Literature DB >> 33592059

Genomic and RT-qPCR analysis of trimethoprim-sulfamethoxazole and meropenem resistance in Burkholderia pseudomallei clinical isolates.

Marine Schnetterle1,2, Olivier Gorgé1, Flora Nolent1, Aïda Boughammoura1, Véronique Sarilar3, Cécile Vigier1, Sophie Guillier1, Lionel Koch1,2, Nicolas Degand4, Vincent Ramisse5, Xavier Tichadou5, Maria Girleanu6, Anne-Laure Favier6, Eric Valade1,2, Fabrice Biot1, Fabienne Neulat-Ripoll1.   

Abstract

BACKGROUND: Melioidosis is an endemic disease in southeast Asia and northern Australia caused by the saprophytic bacteria Burkholderia pseudomallei, with a high mortality rate. The clinical presentation is multifaceted, with symptoms ranging from acute septicemia to multiple chronic abscesses. Here, we report a chronic case of melioidosis in a patient who lived in Malaysia in the 70s and was suspected of contracting tuberculosis. Approximately 40 years later, in 2014, he was diagnosed with pauci-symptomatic melioidosis during a routine examination. Four strains were isolated from a single sample. They showed divergent morphotypes and divergent antibiotic susceptibility, with some strains showing resistance to trimethoprim-sulfamethoxazole and fluoroquinolones. In 2016, clinical samples were still positive for B. pseudomallei, and only one type of strain, showing atypical resistance to meropenem, was isolated. PRINCIPAL
FINDINGS: We performed whole genome sequencing and RT-qPCR analysis on the strains isolated during this study to gain further insights into their differences. We thus identified two types of resistance mechanisms in these clinical strains. The first one was an adaptive and transient mechanism that disappeared during the course of laboratory sub-cultures; the second was a mutation in the efflux pump regulator amrR, associated with the overexpression of the related transporter.
CONCLUSION: The development of such mechanisms may have a clinical impact on antibiotic treatment. Indeed, their transient nature could lead to an undiagnosed resistance. Efflux overexpression due to mutation leads to an important multiple resistance, reducing the effectiveness of antibiotics during treatment.

Entities:  

Year:  2021        PMID: 33592059      PMCID: PMC7909661          DOI: 10.1371/journal.pntd.0008913

Source DB:  PubMed          Journal:  PLoS Negl Trop Dis        ISSN: 1935-2727


  64 in total

1.  Raising the Stakes: Loss of Efflux Pump Regulation Decreases Meropenem Susceptibility in Burkholderia pseudomallei.

Authors:  Derek S Sarovich; Jessica R Webb; Matthew C Pitman; Linda T Viberg; Mark Mayo; Robert W Baird; Jennifer M Robson; Bart J Currie; Erin P Price
Journal:  Clin Infect Dis       Date:  2018-07-02       Impact factor: 9.079

2.  Exposing a β-Lactamase "Twist": the Mechanistic Basis for the High Level of Ceftazidime Resistance in the C69F Variant of the Burkholderia pseudomallei PenI β-Lactamase.

Authors:  Krisztina M Papp-Wallace; Scott A Becka; Magdalena A Taracila; Marisa L Winkler; Julian A Gatta; Drew A Rholl; Herbert P Schweizer; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2015-11-23       Impact factor: 5.191

Review 3.  Melioidosis.

Authors:  W Joost Wiersinga; Harjeet S Virk; Alfredo G Torres; Bart J Currie; Sharon J Peacock; David A B Dance; Direk Limmathurotsakul
Journal:  Nat Rev Dis Primers       Date:  2018-02-01       Impact factor: 52.329

4.  Evolution of Burkholderia pseudomallei in recurrent melioidosis.

Authors:  Hillary S Hayden; Regina Lim; Mitchell J Brittnacher; Elizabeth H Sims; Elizabeth R Ramage; Christine Fong; Zaining Wu; Eva Crist; Jean Chang; Yang Zhou; Matthew Radey; Laurence Rohmer; Eric Haugen; Will Gillett; Vanaporn Wuthiekanun; Sharon J Peacock; Rajinder Kaul; Samuel I Miller; Colin Manoil; Michael A Jacobs
Journal:  PLoS One       Date:  2012-05-15       Impact factor: 3.240

5.  Efflux pump-mediated drug resistance in Burkholderia.

Authors:  Nicole L Podnecky; Katherine A Rhodes; Herbert P Schweizer
Journal:  Front Microbiol       Date:  2015-04-14       Impact factor: 5.640

6.  Whole-Genome Sequences of Burkholderia pseudomallei Isolates Exhibiting Decreased Meropenem Susceptibility.

Authors:  Erin P Price; Melissa Laird Smith; Ellen E Paxinos; Luke J Tallon; Lisa Sadzewicz; Naomi Sengamalay; Robert W Baird; Bart J Currie; Derek S Sarovich
Journal:  Genome Announc       Date:  2017-04-06

7.  Fast and accurate short read alignment with Burrows-Wheeler transform.

Authors:  Heng Li; Richard Durbin
Journal:  Bioinformatics       Date:  2009-05-18       Impact factor: 6.937

8.  Within-host evolution of Burkholderia pseudomallei over a twelve-year chronic carriage infection.

Authors:  Erin P Price; Derek S Sarovich; Mark Mayo; Apichai Tuanyok; Kevin P Drees; Mirjam Kaestli; Stephen M Beckstrom-Sternberg; James S Babic-Sternberg; Timothy J Kidd; Scott C Bell; Paul Keim; Talima Pearson; Bart J Currie
Journal:  MBio       Date:  2013-07-16       Impact factor: 7.867

9.  Perturbation of the two-component signal transduction system, BprRS, results in attenuated virulence and motility defects in Burkholderia pseudomallei.

Authors:  Natalie R Lazar Adler; Elizabeth M Allwood; Deanna Deveson Lucas; Paul Harrison; Stephen Watts; Alexandra Dimitropoulos; Puthayalai Treerat; Priyangi Alwis; Rodney J Devenish; Mark Prescott; Brenda Govan; Ben Adler; Marina Harper; John D Boyce
Journal:  BMC Genomics       Date:  2016-05-04       Impact factor: 3.969

10.  Formaldehyde and Glutaraldehyde Inactivation of Bacterial Tier 1 Select Agents in Tissues.

Authors:  Jennifer Chua; Joel A Bozue; Christopher P Klimko; Jennifer L Shoe; Sara I Ruiz; Christopher L Jensen; Steven A Tobery; Jared M Crumpler; Donald J Chabot; Avery V Quirk; Melissa Hunter; David E Harbourt; Arthur M Friedlander; Christopher K Cote
Journal:  Emerg Infect Dis       Date:  2019-05-17       Impact factor: 6.883

View more
  1 in total

1.  Investigation of a combination therapy approach for the treatment of melioidosis.

Authors:  Kay B Barnes; Mark I Richards; Gary Burgess; Stuart J Armstrong; Christine Bentley; Thomas C Maishman; Thomas R Laws; Michelle Nelson; Sarah V Harding
Journal:  Front Microbiol       Date:  2022-08-16       Impact factor: 6.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.